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Clotting blood contains ﬁbrin-bound thrombin, which is a major source of procoagulant activity leading to clot extension and
further activation of coagulation. When bound to ﬁbrin, thrombin is protected from inhibition by antithrombin (AT) + heparin
but is neutralized when AT and heparin are covalently linked (ATH). Here, we report the surprising observation that, rather than
yielding an inert complex, thrombin-ATH formation converts clots into anticoagulant surfaces that eﬀectively catalyze inhibition
of thrombin in the surrounding environment.
Copyright © 2008 Lesley J. Smith et al. Thisisan open access articledistributedunder theCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Thrombosis results from stimulation of the coagulation
pathway, which leads to thrombin cleavage of ﬁbrinogen
to form ﬁbrin. During this process, thrombin becomes
incorporated into the evolving ﬁbrin clot and becomes a
nidus for activation of coagulant factors and ﬁbrin accretion
[1]. Historically, thrombosis prevention has been through
administration of heparin, which catalyzes the inhibition
of thrombin by antithrombin (AT) [2]. Paradoxically, use
of heparin can actually lead to protection of ﬁbrin-bound
thrombin from reaction with noncovalent AT•heparin by
forming a ﬁbrin•heparin•thrombin ternary complex [3].
Increased heparin concentrations reduce circulating pro-
thrombotic activity but clot-associated thrombin activity
reappears once heparin treatment is discontinued [3, 4]. We
developed a potent nondissociable covalent complex of AT
and heparin (ATH) [5] so that attraction of the heparin
moiety to ﬁbrin•thrombin would consequently neutralize
thrombin via the attached AT [6]. Investigation of ATH
interactions with ﬁbrin monomer and thrombin revealed
that the covalent thrombin-ATH complex formed remains
adherent to ﬁbrin through the heparin chain [6]. We
were intrigued to determine if the heparin in ﬁbrin-bound
thrombin-ATH may still be able to interact with exogenous
ﬂuid-phase coagulation proteins. Thus, the present work was
designed to determine if the heparin chain in the thrombin-
ATH complexes bound to ﬁbrin monomer and ﬁbrin clot
surfaces is capable of catalyzing the inhibition of free, ﬂuid
phase, thrombin by exogenously added AT.
2.MaterialsandMethods
2.1. FibrinMonomer Preparation
Soluble ﬁbrin monomer was prepared from human ﬁb-
rinogen (Enzyme Research Laboratories), after removal
of contaminating ﬁbronectin by incubation of 15mL of
130µM ﬁbrinogen with 5mL of gelatin agarose (Sigma) for
30minutes.Puriﬁedﬁbrinogen(100µM)wasincubatedwith
human thrombin (Enzyme Research, 2nM ﬁnal) at 37◦Cf o r
4hours, followed by centrifugation for 5minutes at 2000g.
The ﬁbrin polymer pellet was placed in dialysis tubing
with a 12000–14000MW cutoﬀ and dialyzed at 4◦Cv e r s u s
H2O, followed by dialysis against 0.02M acetic acid until
the ﬁbrin dissolved. The ﬁbrin monomer concentration was
determined by absorbance at 280nm, where a concentration
of 10mg/mL = an absorbance of 14.0.
2.2. Complex Preparation
Covalent antithrombin-heparin complex (ATH) was pre-
pared by heating 1152mg of antithrombin (AT; Aﬃnity2 Research Letters in Biochemistry
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Figure 1: Catalysis of thrombin inhibition by anticoagulant bound
topuriﬁedﬁbrin.Thrombinonﬁbrinwasmixedwithantithrombin
(AT) + heparin (H) or covalent antithrombin-heparin (ATH)
and ability to accelerate reaction of additional thrombin + AT
determined as the decrease in percent thrombin activity remaining
compared to experiments without H or ATH. Data are expressed as
mean ± SEM and n ≥ 6. ∗∗P<. 01, using a t-test relative to ATH.
Biologicals Inc.) + 64g of heparin (Sigma) in 900mL of PBS
for 14days at 40◦C. Following incubation, NaBH3CN was
addedtoaﬁnalconcentrationof0.05Mandthesolutionwas
further incubated at 37◦C for 5hours. Free AT was removed
bymakingthereactionmixture2.5Min(NH4)2SO4,loading
on a 1000mL column of butyl sepharose (Amersham),
washing the beads with 2.5M (NH4)2SO4 and eluting the
complex in 0.02 M phosphate pH 7.0. Eluent was dialyzed
versus 0.01M Tris-HCl pH 8.0 buﬀer and bound to 900mL
of DEAE sepharose (Amersham), followed by washing with
0.2M NaCl in buﬀer and elution of puriﬁed ATH with 2.0M
NaCl in buﬀer. ATH was pressure-dialyzed versus PBS. The
ﬁnal puriﬁed ATH product possessed <5% unconjugated
starting materials and contained AT which was >95% active
against thrombin. Previous work has established that the AT
: heparin molar ratio is essentially 1 : 1 [5].
2.3. Sepharose-AT Chromatography
High-aﬃnity heparin (HAH) was prepared by loading 4mg
of heparin (in 2mL of 0.15M NaCl in 0.01M phosphate
pH 7.3 buﬀer) on a 10mL column of sepharose-AT pre-
pared from AT and CNBr-activated sepharose (Amersham),
accordingtothemanufacturer.Thecolumnwasthenwashed
with0.5MNaClinbuﬀerandelutedwith2MN aClinbuﬀer.
Recovered HAH was dialyzed against H2O and lyophilized.
2.4. FibrinMonomer andThrombin Inhibition
In order, 3.24µLo f3 7µM ﬁbrin monomer, 2.54µLo f5 9µM
GPRP-NH2 (Sigma), 1.3µL of 1M Tris, 4.6µL0 . 0 2MT r i s -
HCl 0.15 M NaCl 0.6% polyethylene glycol 8000 pH 7.4
(TSP), 2.06µL of 1mg/mL bovine albumin (globulin free;
Sigma) in TSP, and 1.2µLo f1 . 0 8µM thrombin were mixed
at23◦Cinamicrofugetube.After2minutes,2.06µLofeither
0.125µM AT + 0.125µM heparin or 0.125µMA T Hw a s
added. Following a further 2-minute incubation, TSP solu-
tions of excess AT (12.9µM, 1µL) and thrombin (1.08µM,
12µL) were added in rapid succession. After 2minutes of
reaction, remaining thrombin activity was determined by
mixing0.8µLofreactionmixturewith79.2µLof0.62mMS-
2238 substrate (diaPharma, West Chester, OH, USA) in TSP,
followed by neutralization after 10minutes with 20µLo f
50% acetic acid and measurement of absorbance at 405nm.
The ability to catalyze the inhibition of thrombin by AT
was calculated as the percent decrease in thrombin activity
relative to experiments without AT + heparin or ATH.
2.5. FibrinClots andThrombin Inhibition
A volume of 0.5mL of plasma was mixed with 9µLo f1M
CaCl2 in microfuge tubes containing 6mm plastic loops
(Fisher). After 1hour at 37◦C, clots (on loops) were removed
and washed 6 times by dipping in 1mL solutions of 0.02M
Tris-HCl 0.15M NaCl pH 7.4 (TBS). After storage overnight
at 4◦C in TBS, clots were placed in TBS for 20minutes at
23◦Ca n d1 h o u ra t3 7 ◦C, followed by 6 TBS washes and
storage overnight at 4◦C in TBS. Clots were placed in fresh
TBS for 20minutes and then incubated for 1hour at 37◦Ci n
1mL of either TSP, 0.1µMA T+0 . 1µM heparin; TSP, 0.1µM
AT + 0.1 µM HAH; or TSP, 0.1µM ATH. After washing
brieﬂy 6 times in 1mL of TSP and once for 20minutes in
TSP at 23◦C, catalytic activity of the clots was determined at
37◦C in a solution of 0.5mL 0.043µM thrombin + 0.5mL
0.2µM AT, mixed just prior to use. Clots were dipped up
and down (once per second) within the thrombin + AT
solution for 1 minute. After removal of the clot, 12µLo f
the thrombin + AT solution was reacted with 67.2µLo f
0.71mM S-2238 in TSP for 10minutes at 23◦C, neutralized
with 20µL of 50% acetic acid and the absorbance was taken
at 405nm to determine activity. Results were calculated as a
percent of thrombin activity in thrombin solutions without
AT. Inhibition was determined relative to reactions without
clots. Subtraction of percent thrombin activity lost in clots
incubated without heparin compounds gave the net catalytic
activity observed.
2.6. StatisticalAnalyses
Data were judged to be normally distributed since variance
about the mean was not skewed and application of the
Anderson-Darling normality test did not reveal any non-
Gaussian distributions. t-tests (2 tailed, nonpaired) were
used for the ﬁbrin monomer studies (n ≥ 6), as there were
two main experimental groups. Since there were multiple
groups in the ﬁbrin clot experiments, a one-way ANOVA
was performed (n ≥ 4, P = .004), followed by the Tukey
posttestforcomparisonsbetweenATHandtheotherheparin
experimental groups. An alpha level of 0.05 was used
throughout the analyses. Data are expressed as mean ±
standard error of the mean (SEM).Research Letters in Biochemistry 3
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Figure 2: Catalysis of thrombin inhibition by anticoagulant bound
to ﬁbrin clots. Recalciﬁed plasma clots were incubated with
antithrombin (AT) + heparin (H), AT + high AT-aﬃnity heparin
(HAH) or antithrombin-heparin covalent complex (ATH), and
increase in percent inhibition of soluble thrombin by AT calculated
relative to clots in buﬀer. Data are expressed as mean ± SEM and
n ≥ 4. ∗P<. 05, using the Tukey test (after one-way ANOVA) for
determination of signiﬁcant diﬀerences relative to ATH.
3.Results andDiscussion
Initial experiments were conducted to ensure that thrombin
on ﬁbrin was neutralized by ATH and that the inhibited
surface did not protect additional free thrombin from
attack by ﬂuid-phase AT. Results from chromogenic assays
showed that ﬁbrin•thrombin-ATH had no eﬀect on soluble
thrombin functional activity. While all thrombin on ﬁbrin
was capable of reaction with ATH, a rapid inactivation of
supplemental thrombin ensued in the presence of exogenous
AT. Careful studies conﬁrmed that, compared to ﬁbrin alone,
thrombin-ATH on ﬁbrin signiﬁcantly catalyzed inhibition of
excess thrombin by AT (P = .007) while similar tests with
noncovalent AT + heparin mixtures demonstrated no eﬀect
(Figure 1).
We next examined the capacity for surface antico-
agulation of ATH in a physiological system. Clots from
recalciﬁed plasma were treated with buﬀer or small amounts
of ATH. Incubation of thrombin + AT solutions with
ATH-neutralized clots showed strong inhibition of enzyme
activity relative to AT + heparin or AT + heparin with
high aﬃnity for AT (HAH), with P values of 0.026 and
0.023, respectively (Figure 2). Moreover, insigniﬁcant eﬀects
on soluble thrombin + AT were observed for clots treated
with either AT + heparin or AT + HAH (95% conﬁdence
intervals of −17.2–19.1 and −2.2–10.2, resp.). Thus, we
have demonstrated that not only does ATH inactivate clot
prothrombotic activity, but the surface produced on the clot
also contains heparin which maintains anticoagulant activity
in the surrounding milieu. This ﬁnding is in contrast to
that with heparin, where heparin absorbed on procoagulant
clots was ineﬀective at inﬂuencing thrombin/AT reactions
(Figure 2). Furthermore, the lack of enhancement by HAH
of thrombin reaction with AT (Figure 2) conﬁrmed that
enrichment of high-aﬃnity AT binding sites in the heparin
(a)
+
(b)
Figure3:Modelofcatalysisofthrombininhibitionbyﬁbrin-bound
antithrombin-heparin covalent complex (ATH). The ﬁbrin (blue)
clot-bound thrombin-ATH (thrombin in yellow, antithrombin
(AT)ingreen,heparininred)isabletocatalyzethrombininhibition
byATsincetheheparinchainisavailabletobindbothfreethrombin
and AT (panel (a)). In the case of noncovalently linked heparin, the
heparin-catalyzed inhibition of thrombin by AT is negated through
theformationofa ﬁbrin-thrombin-heparinternarycomplex (panel
(b)).
chains of clot-bound ATH [5] was not responsible for ATH’s
superior catalytic properties.
Am o d e l( Figure 3) shows the thrombin-ATH complex,
noncovalently tethered through heparin to ﬁbrin, which
is catalyzing reaction of incoming thrombin + AT via
conventionalheparintemplatebridging[7].Thismechanism
is consistent with data showing that ATH causes reduction
in clot size within injured vessels, compared to clot growth
which occurs with AT + heparin [8]. Our ﬁndings have
implications that could alter treatment paradigms. By “coat-
ing” ﬁbrin-thrombi with ATH, clinicians may use clots as
platforms to pacify hyperthrombotic activity in damaged
vasculature.
4.Conclusions
Covalent linkage of AT to heparin facilitates formation of
ﬁbrin clot-bound structures with heparin moieties possess-
ingpotentthrombin-inhibitorycatalyticactivity.Conversion
of clot surfaces into functional anticoagulants may be done
selectively since ATH heparin chains are electrostatically
attracted to ﬁbrin•thrombin [6]. In vivo experiments will
conﬁrm the utility of anticoagulated thrombi in treatment
models.
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